title: Evolving ablative therapies for hepatic malignancy.
abstract: The liver is a common site for both primary and secondary malignancy. Hepatic resection and transplantation are the two treatment modalities that have been shown to achieve complete cure, but only 10 to 20% of patients are candidates for these treatments. For the remaining patients, tumor ablation has emerged as the most promising alternative modality. In addition to providing local control and improving survival outcomes, tumor ablation also helps to down stage patients for potential curative treatments, both alone as well as in combination with other treatments. While tumor ablation can be achieved in multiple ways, the introduction of newer ablative techniques has shifted the focus from palliation to potentially curative treatment. Because the long-term safety and survival benefits are not substantive at present, it is important that we strive to evaluate the results from these studies using appropriate comparative outcome methodologies.
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA.
authors.forename: Smit
authors.identifier: 0000-0002-9193-6351
authors.initials: S
authors.lastname: Singla
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA.
authors.forename: Steven N
authors.initials: SN
authors.lastname: Hochwald
authors.affiliation: Roswell Park Cancer Institute, Elm and Carlton Street, Buffalo, NY 14263, USA.
authors.forename: Boris
authors.identifier: 0000-0002-2550-792X
authors.initials: B
authors.lastname: Kuvshinoff
mesh_terms: D018572:Disease-Free Survival; D006801:Humans; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D015996:Survival Rate